newsfilter
← Latest News
GlobeNewswire·

Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened, is ongoing. Sol-Gel and Beimei Pharma announced an Asset Purchase Agreement to commercialize TWYNEO® in China, Hong Kong, Macau,